ALDX Q4 2023 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$66,469

Operating Income

-$6M

Net Income

-$5M

EPS (Diluted)

$-0.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$500,440

Free Cash Flow

$500,440

Stock-Based Comp.

-$800,341

Balance Sheet

Total Assets

$148M

Total Liabilities

$29M

Stockholders' Equity

$120M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$66,469	-$66,643	+0.3%
Operating Income	-$6M	-$14M	+55.5%
Net Income	-$5M	-$13M	+63.2%